GeoVax Labs, Inc. (OTCMKTS:GOVX) is on an explosive rise up the charts in recent days running off its $0.50 base and surging over $1 with strength transforming into a volume leader in small caps. David Dodd, Geovax CEO was getting onto fox news regularly earlier this year and this run up too was helped along by his recent appearance on Shannon Bream during which he stated they terminated China connection. LOI not signed and they going it alone.
GOVX initially started to rise earlier this year after the Company announced they were working together with BravoVax, a vaccine developer in Wuhan, China to jointly develop a vaccine against the coronavirus (covid-19). The move up accelerated after the after the World Health Organziation (WHO) listed Geovax and BravoVax on its list of possible COVID-19 candidate vaccines. Microcapdaily has been covering GeoVax along the way.
GeoVax Labs, Inc. (OTCMKTS:GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel proprietary vaccine platform (GV-MVA-VLPTM). On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine (in vivo). The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The GV-MVA-VLPTM derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while typically providing the safety characteristics of a replication-defective vector.
GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China. According to GOVX the Company has seen rapid progress with design, construction and in vitro characterizations of its three vaccine candidates. From here, GOVX will narrow to one vaccine candidate based on the safety, immunogenicity and protective efficacy of our PreMaster Seed Viruses observed in upcoming animal studies. The final candidate will then proceed directly to manufacturing and initial human clinical testing for safety and immunogenicity.
To Find out the inside Scoop on GOVX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
GeoVax’s COVID-19 vaccine effort, currently in animal challenge testing, is based on a unique multi-antigen approach utilizing its Modified Vaccinia Ankara Virus Like Particles (GV-MVA-VLPTM) platform technology. GV-MVA-VLPTM is built on a proprietary MVA vector system that is optimized for high expression and stable transgenes during manufacture. Similar to its parent MVA, it has the advantages of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells for vaccination, thus inherently safe. Importantly, GV-MVA-VLPTM vaccines elicit protective T cell as well as antibody responses (Th1 biased) in animals and humans. In non-clinical studies, GV-MVA-VLPTM vaccine candidates against various virus families (e.g. Ebola, Marburg, Lassa and Zika) induced strong antibody and T cell responses and conferred full protection after single dose vaccinations against lethal challenges. Single dose protection is a favourable characteristic of preventive vaccines for response to an emerging infectious disease outbreak, given the speed of spread of pathogens and the impracticality of multi-dose regimens in the under-resourced settings where outbreaks often occur.
— kubsv (@kubsv) July 21, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Microcapdaily has been covering Geovax for years since the stock was trading for pennies and we covered it when it hit $0.19 lows the first time in 2014. During the Ebola crisis GOVX popped because the Company said they were working on a vaccine, same with Zika. During the coronavirus pandemic Geovax has developed a unique multi-antigens approach toward COVID-19 vaccine development. The Companies Modified Vaccinia Ankara Virus-Like Particles (GV-MVA-VLPTM) platform technology is built on a proprietary MVA vector system that is optimized for high expression and stable transgenes during manufacture. Similar to its parent MVA, it has the advantages of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells for vaccination, thus inherently safe. The Geovax story has seen plenty of exposure due to its CEO making regular appearances on FOX NEWS. We will be updating on GOVX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GOVX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in GOVX either long or short and we have not been compensated for this article.